Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2645-2652

  Jones, M E ^a   Staples, A M ^a   Critchley, I ^a   Thornsberry, C ^a   Heinze, P ^a   Engler, H D ^a   Sahm, D F ^a  

^a MRL Pharmaceutical Services   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATION; CLONE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME SYNTHESIS; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; BACTERIA; CLONING, MOLECULAR; COMPARATIVE STUDY; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GENOTYPE; HAEMOPHILUS INFLUENZAE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PHENOTYPE; RESPIRATORY TRACT INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T; UNITED STATES;

EID: 0033802361     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2645-2652.2000     Document Type: Article

References (46)

1. World-wide development of antibiotic resistance in pneumococci
2. Comparative in vitro assessment of the activity and spectrum using results from over 14,000 pathogens isolated from 190 centers in the U.S.
3. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study
4. Bacteriology
5. Community-acquired pneumonia
6. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
7. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian bacterial surveillance network
8. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian bacterial surveillance network
9. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone
10. Anti-microbial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994-1995: Results of a 30-center national surveillance study
11. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
12. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander project 1992-1996
13. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: First results from the SENTRY Antimicrobial Surveillance Program 1997
14. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
15. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland
16. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
17. Prevalence of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season
18. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment
19. Benchmarking the activity of moxifloxacin against recent clinical isolates of Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. A European multi-center study
20. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
21. Pneumococcal resistance to antibiotics
22. BA Y12-8039, a new 8-methoxy-quinolone: Comparative in vitro activity with nine other antimicrobials against anaerobic bacteria
23. Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae
24. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
25. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
26. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
27. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
28. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
29. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
30. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program
31. Moxifloxacin: A comparison with other antimicrobial agents of in vitro activity against Streptococcus pneumoniae
32. Sensitivity to sparfloxacin and other antibiotics of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adults with community acquired lower respiratory tract infections: A European multi centre study
33. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
34. Trends in the activity of macrolide and β-lactam antibiotics and resistance development
35. Characterization of grlA, grlB, gyrA, and gyrB in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC
36. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activity of ciprofloxacin, spafftoxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
37. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens
38. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
39. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing
40. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group
41. In vitro activity of grepafloxacin and 25 other antimicrobials against Streptococcus pneumoniae: Correlation with penicillin resistance
42. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States, 1997-1998
43. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
44. In vitro activity of BAY 12-8039, a new fluoroquinolone